Oncology Institute (TOI) Gross Margin (2021 - 2026)

Oncology Institute has reported Gross Margin for 6 years, with the latest figure at 94.39% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 2447.0% year-over-year to 94.39%; the trailing twelve-month figure through Mar 2026 stood at 86.28% (down 1183.0% YoY), and the FY2025 full-year result was 56.13%, down 4354.0% from the prior year.
• Gross Margin for Q1 2026 stood at 94.39%, up from 53.13% in the prior quarter.
• The five-year high for Gross Margin was 210.1% in Q4 2024, with the low at 43.62% in Q4 2023.
• Historically, Gross Margin has averaged 75.09% across 5 years, with a median of 59.87% in 2024.
• Annual changes were most pronounced in 2024 — Gross Margin soared 16648 bps — and 2025, when it sank 15697 bps.
• Oncology Institute's Gross Margin stood at 99.83% in 2022, then plunged by 56 bps to 43.62% in 2023, then soared by 382 bps to 210.1% in 2024, then slumped by 75 bps to 53.13% in 2025, then surged by 78 bps to 94.39% in 2026.
• The last three Gross Margin figures came in at 94.39% (Q1 2026), 53.13% (Q4 2025), and 100.0% (Q3 2025), per Business Quant data.